For a third time, Sarepta Therapeutics has convinced a top Food and Drug Administration official to overrule the prevailing view of their staff and approve a drug for Duchenne muscular dystrophy.
https://www.statnews.com/2024/06/20/sarepta-duchenne-elevidys-fda-approval-peter-marks-overruled-staff/
STAT /
npub1ev…0tvkk
2024-06-21 14:35:05
Author Public Key
npub1evr7plejrksuyjd3xvvy63eugyjh5sf3jlt33wagqdwgcatxc95sw0tvkkPublished at
2024-06-21 14:35:05Event JSON
{
"id": "4eb9608348569a1898fe815c2b6c692af20c6364c2632fb30275597f85a3e670",
"pubkey": "cb07e0ff321da1c249b133184d473c41257a413197d718bba8035c8c7566c169",
"created_at": 1718980505,
"kind": 1,
"tags": [
[
"proxy",
"https://newsie.social/users/STAT/statuses/112655106420600836",
"activitypub"
]
],
"content": "For a third time, Sarepta Therapeutics has convinced a top Food and Drug Administration official to overrule the prevailing view of their staff and approve a drug for Duchenne muscular dystrophy.\n\nhttps://www.statnews.com/2024/06/20/sarepta-duchenne-elevidys-fda-approval-peter-marks-overruled-staff/",
"sig": "aa0b7241e0907bd60460c4e50dfd4bae5737922dfe2b38389038afa6bef082e9efa598837590651230c068925356392b8f926d9429b47b316bccf8948db53879"
}